Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rats.
about
In vitro and in vivo activities of NS-718, a new lipid nanosphere incorporating amphotericin B, against Aspergillus fumigatusComparative neurotoxicities of amphotericin B and its mono-methyl ester derivative in ratsPractice guidelines for lipid-based amphotericin B in stem cell transplant recipients.Dose-dependent antifungal activity and nephrotoxicity of amphotericin B colloidal dispersion in experimental pulmonary aspergillosisPhysiologically based pharmacokinetic model of amphotericin B disposition in rats following administration of deoxycholate formulation (Fungizone®): pooled analysis of published data.An optimized nanoparticle delivery system based on chitosan and chondroitin sulfate molecules reduces the toxicity of amphotericin B and is effective in treating tegumentary leishmaniasisScaling basic toxicokinetic parameters from rat to man.The amphotericin B lipid complex or Abelcet: its Belgian connection, its mode of action and specificity: a review.Therapeutic monitoring of experimental invasive pulmonary aspergillosis by ultrafast computerized tomography, a novel, noninvasive method for measuring responses to antifungal therapy.Population pharmacokinetics and renal function-sparing effects of amphotericin B colloidal dispersion in patients receiving bone marrow transplantsProtein-functionalized PLGA nanoparticles of lamotrigine for neuropathic pain management.Carrier effects on biological activity of amphotericin B.Relationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs.Antifungal therapy and outcomes in infants with invasive Candida infections.Pharmacokinetics of amphotericin B colloidal dispersion in critically ill patients with cholestatic liver diseaseAn update on the use of antifungal agents.Efficacy and safety of amphotericin B colloidal dispersion compared with those of amphotericin B deoxycholate suspension for treatment of disseminated murine cryptococcosis.Recent approaches to antifungal therapy for invasive mycoses.Tissue penetration of antifungal agents.Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications.Clinical Pharmacokinetics of Systemically Administered Antileishmanial Drugs.An 8-hydroxyquinoline-containing polymeric micelle system is effective for the treatment of murine tegumentary leishmaniasis.Comparative toxicities and pharmacokinetics of intrathecal lipid (amphotericin B colloidal dispersion) and conventional deoxycholate formulations of amphotericin B in rabbitsComparison of antifungal activity of amphotericin B deoxycholate suspension with that of amphotericin B cholesteryl sulfate colloidal dispersion.Tissue pharmacokinetics and pharmacodynamics of AmBisome® (L-AmBis) in uninfected and infected animals and their effects on dosing regimens.In search of the amazing technicolour dream coat for amphotericin B.Amphotericin B: time for a new "gold standard".Dual physiologically based pharmacokinetic model of liposomal and nonliposomal amphotericin B disposition.Pharmacokinetics and tissue distribution of amphotericin B following oral administration of three lipid-based formulations to rats.Liposomal and Deoxycholate Amphotericin B Formulations: Effectiveness against Biofilm Infections of Candida spp.Liposomal amphotericin B in travelers with cutaneous and muco-cutaneous leishmaniasis: Not a panacea.Leishmaniasis in humans: drug or vaccine therapy?AmBisome (liposomal amphotericin B): a comparative review.
P2860
Q28343158-CB95F7E4-1F80-4A1B-892B-A769547D4200Q28378621-6139527C-53C2-462A-A22A-AD41E05B4129Q32052950-48F33055-CC23-4F83-B1A7-DA6CE9F8AAF6Q33751032-BCF9AEB7-5543-4654-82F2-34AA1AA89F19Q33853860-A3CF3A02-94B2-4D7C-8FE4-81BD28FBF670Q34565059-678C195F-FF29-4F89-9AE4-6690880B1DD2Q34635619-62DE3117-80EA-42B4-8A64-9CDEDC87D9E8Q34769519-134FA50F-6003-44A8-AD54-AAC677E714CCQ35114249-7C707F40-1662-4A7B-A7B5-77585A8AB51BQ35118404-5C3228F4-C097-4B2D-84E4-106183DFF7E2Q35209969-3DCEFC18-2245-4713-B6DB-530508682613Q35372581-703CC006-A866-4288-9C71-8EEE0D8D53FEQ35825552-0986C6F5-1E7A-4248-99AC-35C1F1A991A9Q35897495-B70CE854-4BC1-44A9-8877-A649EE7A4853Q36276845-B399B35F-CA04-4D64-A6A1-9D3AEECAF9CFQ36724783-1AB4D1E7-FB59-403E-8A96-1D5F27731932Q36758184-72FCC479-1C09-4C73-B6BC-E16C40CAD737Q37377752-9EAA7E60-73BC-41A2-A186-CD10CEB4828BQ37544911-ACDBFDE5-1218-44FC-BF33-FF20D559C45AQ38193337-625DE85A-6A15-47D9-9A97-56B41B456308Q38653256-2785F3CE-E1AF-455E-8DF0-4BD2A74CEED6Q39156596-F06D6D24-B555-4EC1-BB1C-2A264AB14EECQ39476373-2FA0024F-2619-4B43-BD70-B88257F2DFB3Q39868009-99E7E112-E9BC-4F2B-9832-AE33801E2002Q40222438-3D20149A-9E10-44D3-A28D-3B4227853093Q42544559-2B4C2589-0C2B-402B-A139-ECBE7A399A51Q44527998-BB7EF4D1-96D3-4D6E-A441-C546C088232DQ44786792-686F9238-A315-4653-AC0C-AF06A99316B1Q45850524-5AD4ECA9-E078-485B-8C39-A62C57D3BB22Q46250284-14612ABB-FBB3-4ADE-9DF2-CE0422276341Q46258168-8AE3A35D-54FF-4F49-9709-FB60BD28C290Q47556262-355B4182-9473-46F2-938C-F87D7AAA8E32Q52531516-193DE05B-1C53-4C38-8ABD-A1C25A1E33D8
P2860
Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rats.
description
1991 nî lūn-bûn
@nan
1991 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1991 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
name
Comparative pharmacokinetics o ...... ventional formulation to rats.
@ast
Comparative pharmacokinetics o ...... ventional formulation to rats.
@en
type
label
Comparative pharmacokinetics o ...... ventional formulation to rats.
@ast
Comparative pharmacokinetics o ...... ventional formulation to rats.
@en
prefLabel
Comparative pharmacokinetics o ...... ventional formulation to rats.
@ast
Comparative pharmacokinetics o ...... ventional formulation to rats.
@en
P2093
P2860
P356
P1476
Comparative pharmacokinetics o ...... ventional formulation to rats.
@en
P2093
P2860
P304
P356
10.1128/AAC.35.6.1208
P407
P577
1991-06-01T00:00:00Z